Who owns PLRX?
Institutional ownership of Pliant Therapeutics Inc. from Form 13F, Q2 2026
86 institutional managers reported holding Pliant Therapeutics Inc. (PLRX) in Form 13F filings for Q2 2026, with 48,100,481 shares worth $54.8M. The largest reported holder was Tang Capital Management LLC. Managers that filed both quarters cut a net 1,580,689 shares (-3.2%). 8 opened new positions and 13 sold out.
- Funds holding
- 86
- Value held
- $54.8M
- New / sold out
- 8 / 13
- Net shares, same filers
- -3.2%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of PLRX
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Tang Capital Management LLC | $7.0M | 12.8% | 6,141,261 | Unchanged |
| ADAR1 Capital Management, LLC | $6.3M | 11.5% | 5,509,724 | Added |
| Vanguard Capital Management LLC | $2.8M | 5.1% | 2,440,351 | Added |
| Acadian Asset Management LLC | $2.7M | 5.0% | 2,416,508 | Unchanged |
| Two Sigma Investments, LP | $2.6M | 4.7% | 2,262,832 | Added |
| Citadel Advisors LLC | $2.4M | 4.5% | 2,142,226 | Trimmed |
| Renaissance Technologies LLC | $2.3M | 4.3% | 2,049,874 | Added |
| Monaco Asset Management SAM | $2.2M | 4.0% | 1,938,747 | Unchanged |
| Lynx1 Capital Management LP | $2.0M | 3.7% | 1,798,070 | New |
| BML Capital Management, LLC | $1.8M | 3.2% | 1,546,137 | Unchanged |
| Prosight Management, LP | $1.6M | 2.8% | 1,370,233 | Trimmed |
| Peapod Lane Capital LLC | $1.5M | 2.7% | 1,309,013 | Added |
| Woodline Partners LP | $1.5M | 2.7% | 1,296,534 | Trimmed |
| BlackRock, Inc. | $1.3M | 2.4% | 1,151,214 | Added |
| Ikarian Capital, LLC | $1.1M | 2.1% | 1,000,000 | New |
| Eversept Partners, LP | $1.0M | 1.9% | 891,425 | Unchanged |
| Marshall Wace, LLP | $952K | 1.7% | 835,124 | Trimmed |
| Redmile Group, LLC | $880K | 1.6% | 772,126 | Unchanged |
| JPMorgan Chase & Co | $784K | 1.4% | 681,647 | Trimmed |
| Jacobs Levy Equity Management, Inc | $733K | 1.3% | 643,120 | Trimmed |
| Geode Capital Management, LLC | $660K | 1.2% | 578,577 | Added |
| UBS Group AG | $652K | 1.2% | 571,760 | Trimmed |
| Millennium Management LLC | $638K | 1.2% | 559,447 | Trimmed |
| Bridgeway Capital Management, LLC | $631K | 1.2% | 553,630 | Unchanged |
| Connor, Clark & Lunn Investment Management Ltd. | $611K | 1.1% | 536,081 | Added |
Share of 13F holdings is each fund's shares as a share of the 48,100,481 PLRX shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- ADAR1 Capital Management, LLC Added+$3.3M
- Lynx1 Capital Management LP New+$2.0M
- Ikarian Capital, LLC New+$1.1M
- Boothbay Fund Management, LLC New+$345K
- Renaissance Technologies LLC Added+$225K
- Verdad Advisers, LP Added+$209K
- Marquette Asset Management, LLC New+$199K
- Geode Capital Management, LLC Added+$184K
- Vanguard Capital Management LLC Added+$111K
- BlackRock, Inc. Added+$62K
Biggest sellers in Q2 2026
- Blue Owl Capital Holdings LP Sold out-$3.7M
- Citadel Advisors LLC Trimmed-$1.2M
- Millennium Management LLC Trimmed-$708K
- UBS Group AG Trimmed-$554K
- Centiva Capital, LP Sold out-$545K
- Bank of America Corp Sold out-$444K
- Goldman Sachs Group Inc Trimmed-$443K
- Woodline Partners LP Trimmed-$422K
- Prosight Management, LP Trimmed-$339K
- Gsa Capital Partners LLP Trimmed-$274K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $8.1M and sold $10.3M; 18 added and 24 trimmed.
Schedule 13D and 13G filings on PLRX
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-02-09CITADEL ADVISORS LLC SCHEDULE 13G filed by Pliant Therapeutics Inc.Schedule 13G
- 2026-01-31CITADEL ADVISORS LLC SCHEDULE 13G filed by Pliant Therapeutics Inc.Schedule 13G
- 2026-01-23CITADEL ADVISORS LLC SCHEDULE 13G filed by Pliant Therapeutics Inc.Schedule 13G
- 2025-09-04Point72 Asset Management, L.P. SCHEDULE 13G filed by Pliant Therapeutics Inc.Schedule 13G
- 2025-08-06MORGAN STANLEY SCHEDULE 13G filed by Pliant Therapeutics Inc.Schedule 13G
- 2025-03-10TANG CAPITAL MANAGEMENT LLC SCHEDULE 13D filed by Pliant Therapeutics Inc.Schedule 13D
Questions about PLRX ownership
- Who owns PLRX stock?
- 86 institutional investment managers reported PLRX positions in their Form 13F filings for Q2 2026, holding 48,100,481 shares worth $54.8M in total. Tang Capital Management LLC reported the largest position.
- Are funds buying or selling PLRX?
- In Q2 2026, 8 managers opened new PLRX positions, 18 added, 24 trimmed and 13 sold out. Managers that filed in both quarters sold a net 1,580,689 shares.
- How current is this PLRX institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to PLRX by CUSIP. Options are left out. PLRX news and filings · PLRX insider trades · Top funds